1. Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations. (October 2022) Authors: Chicarelli, M.J.; Bouhana, K.; Cable, L.; Crow, M.; Fell, B.; Fischer, J.; Fulton, J.; Guarnieri, A.; Jalluri, R.; Robinson, J.; Sullivan, F.; Winski, S.; Zhou, Y. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗